Nektar Therapeutics (NKTR) EBT Margin (2016 - 2025)
Historic EBT Margin for Nektar Therapeutics (NKTR) over the last 16 years, with Q3 2025 value amounting to 297.04%.
- Nektar Therapeutics' EBT Margin fell 1434700.0% to 297.04% in Q3 2025 from the same period last year, while for Sep 2025 it was 181.81%, marking a year-over-year decrease of 10900.0%. This contributed to the annual value of 121.13% for FY2024, which is 1854000.0% up from last year.
- Nektar Therapeutics' EBT Margin amounted to 297.04% in Q3 2025, which was down 1434700.0% from 352.53% recorded in Q2 2025.
- In the past 5 years, Nektar Therapeutics' EBT Margin registered a high of 23.91% during Q4 2024, and its lowest value of 736.47% during Q2 2022.
- In the last 5 years, Nektar Therapeutics' EBT Margin had a median value of 297.04% in 2025 and averaged 345.98%.
- In the last 5 years, Nektar Therapeutics' EBT Margin tumbled by -2946700bps in 2022 and then skyrocketed by 4868600bps in 2023.
- Quarter analysis of 5 years shows Nektar Therapeutics' EBT Margin stood at 587.02% in 2021, then skyrocketed by 51bps to 288.16% in 2022, then surged by 39bps to 176.29% in 2023, then skyrocketed by 114bps to 23.91% in 2024, then tumbled by -1342bps to 297.04% in 2025.
- Its last three reported values are 297.04% in Q3 2025, 352.53% for Q2 2025, and 443.3% during Q1 2025.